Updates in the treatment of ductal carcinoma in situ of the breast

Current Opinion in Obstetrics and Gynecology

Volumn 28, Issue 1, 2016, Pages 49-58

  Lebeau, Annette ^a   Kühn, Thorsten ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Lübeck and CKlinik Fü R Frauenheilkunde Und Geburtshilfe ^*  (Germany)

Author keywords

Ductal carcinoma in situ; Local failure; Mortality; Treatment

Indexed keywords

ADJUVANT RADIOTHERAPY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE COURSE; FEMALE; HUMAN; MAMMOGRAPHY; MORTALITY; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY; PERSONALIZED MEDICINE; PREVENTION AND CONTROL; PROCEDURES; RISK ASSESSMENT; TRENDS; TUMOR RECURRENCE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; MAMMOGRAPHY; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; PRECISION MEDICINE; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT;

EID: 84952984878     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000237     Document Type: Review

References (45)

1. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002; 94:1546-1554.
2. Narod SA, Iqbal J, Giannakeas V, et al. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 2015; 1:888-896.
3. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of lowgrade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005; 103:2481- 2484.
4. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989; 63:618-624.
5. Burkhardt L, Grob TJ, Hermann I, et al. Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2010; 123:757-765.
6. Early Breast Cancer Trialists' Collaborative G., Correa C, McGale P, Taylor C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010; 2010:162-177.
7. Goodwin A, Parker S, Ghersi D, Wilcken N. Postoperative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev 2013; 11:CD000563.
8. Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. Breast 2014; 23:546- 551.
9. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSA BB-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011; 103:478- 488.
10. Donker M, Litiere S, Werutsky G, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 2013; 31:4054-4059.
11. Wärnberg F, Garmo H, Emdin S, et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol 2014; 32:3613-3618.
12. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011; 12:21-29.
13. Esserman L, Yau C. Rethinking the standard for ductal carcinoma in situ treatment. JAMA Oncol 2015; 1:881-883.
14. Hughes KS. DCIS does not need treatment... really? Breast Cancer Res Treat 2015; 154:1-4.
15. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B- 17: intraductal carcinoma. Cancer 1999; 86:429-438.
16. Group EBCC, Group ER. Bijker N, Meijnen P, Peterse JL, et al. Breastconserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853: A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006; 24:3381-3387.
17. Recht A. Are the randomized trials of radiation therapy for ductal carcinoma in situ still relevant? J Clin Oncol 2014; 32:3588-3590.
18. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 1982; 50:1309-1314.
19. Wang SY, Shamliyan T, Virnig BA, Kane R. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: A metaanalysis. Breast Cancer Res Treat 2011; 127:1-14.
20. Sagara Y, Mallory MA, Wong S, et al. Survival benefit of breast surgery for lowgrade ductal carcinoma in situ: A population-based cohort study. JAMA Surg 2015; 150:739-745.
21. Simpson JF, Schnitt SJ, Visscher D, et al. Atypical ductal hyperplasia. In: S.R. L, I.O. E, S.J. S, PH T, vdV MJ, editors. WHO classifiaction of tumours of the breast, 4th ed Lyon: IARC; 2012. pp. 88-89.
22. Elmore JG, Longton GM, Carney PA, et al. Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA 2015; 313:1122- 1132.
23. Rutgers EJ; Group EC. Quality control in the locoregional treatment of breast cancer. Eur J Cancer 2001; 37:447-453.
24. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996; 77:2267-2274.
25. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999; 340:1455-1461.
26. Ringberg A, Nordgren H, Thorstensson S, et al. Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast-results from the Swedish randomised trial. Eur J Cancer 2007; 43:291-298.
27. Pinder SE, Duggan C, Ellis IO, et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer 2010; 103:94- 100.
28. Wong JS, Chen YH, Gadd MA, et al. Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS). Breast Cancer Res Treat 2014; 143:343-350.
29. Solin LJ, Gray R, Hughes LL, et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-Year results from the ECOG-ACRIN E5194 Study. J Clin Oncol 2015; 33:3938-3944.
30. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 2006; 24:1031- 1036.
31. Lester SC, Bose S, Chen YY, et al. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med 2009; 133:15-25.
32. McCormick B, Winter K, Hudis C, et al. RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 2015; 33:709-715.
33. The Consensus Conference Committee: Consensus Conference on the classification of ductal carcinoma in situ. Cancer 1997; 80:1798-1802.
34. Woodward WA, Sneige N, Winter K, et al. Web based pathology assessment in RTOG 98-04. J Clin Pathol 2014; 67:777-780.
35. Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003; 186:337-343.
36. MacDonald HR, Silverstein MJ, Mabry H, et al. Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. Am J Surg 2005; 190:521-525.
37. Wehner P, Lagios MD, Silverstein MJ. DCIS treated with excision alone using the National Comprehensive Cancer Network (NCCN) guidelines. Ann Surg Oncol 2013; 20:3175-3179.
38. Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 2009; 27:1615-1620.
39. Wang SY, Chu H, Shamliyan T, et al. Network meta-analysis of margin threshold for women with ductal carcinoma in situ. J Natl Cancer Inst 2012; 104:507-516.
40. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013; 105:701-710.
41. Rakovitch E, Nofech-Mozes S, Hanna W, et al. A population-based validation study of the DCIS score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 2015; 152:389- 398.
42. Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol 2010; 28:3762-3769.
43. Sweldens C, Peeters S, van Limbergen E, et al. Local relapse after breast-conserving therapy for ductal carcinoma in situ: A European single-center experience and external validation of the Memorial Sloan-Kettering Cancer Center DCIS nomogram. Cancer J 2014; 20:1-7.
44. Shapiro-Wright HM, Julian TB. Sentinel lymph node biopsy and management of the axilla in ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010; 2010:145-149.
45. Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2014; 32:1365-1383.